Valuation: Alkermes plc

Market Cap 780.9Cr 700.31Cr 645.4Cr 586.13Cr 1.11TCr 73TCr 1.14TCr 7.73TCr 3.08TCr 39TCr 2.93TCr 2.87TCr 1,24000Cr P/E 2026 *
-96.8x
P/E 2027 * 104x
Enterprise Value 886.74Cr 795.22Cr 732.88Cr 665.58Cr 1.26TCr 83TCr 1.29TCr 8.78TCr 3.5TCr 45TCr 3.33TCr 3.26TCr 1,40800Cr EV / Sales 2026 *
4.86x
EV / Sales 2027 * 4.49x
Free-Float
89.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+1.71%
Current month+2.49%
1 month+14.43%
3 months-5.93%
6 months+32.81%
Current year+66.08%
1 week 44.07
Extreme 44.07
47.07
1 month 38.98
Extreme 38.98
47.43
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.06
Extreme 22.06
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Compliance Officer

-2,035 0.0012%
08/10/26 Exercice

Chief Financial Officer

22,397 0.0134%
07/10/26 Free

Director

25,237 0.0150%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+1.71%+42.33%+95.25% 780.9Cr
+1.44%+1.63%+48.17%+139.63% 1,27600Cr
-0.47%+5.49%+49.03%+90.68% 68TCr
+0.20%+2.76%+34.37%+112.06% 52TCr
-0.63%+1.09%+38.62%+67.62% 39TCr
-0.48%+2.34%+70.66%+46.02% 36TCr
-0.71%-0.15%+28.80%+58.43% 31TCr
-0.22%-0.80%+3.31%+35.75% 29TCr
0.00%+0.86%+43.74%+74.04% 25TCr
+0.92%+2.03%+44.62%+125.07% 21TCr
Average -0.08%+2.27%+40.37%+84.45% 43TCr
Weighted average by Cap. -0.19%+2.51%+42.85%+96.69%

Financials

2026 *2027 *
Net sales 182.41Cr 163.59Cr 150.76Cr 136.92Cr 259.13Cr 17TCr 266.36Cr 1.81TCr 719.23Cr 9.16TCr 684.58Cr 670.06Cr 29TCr 192.43Cr 172.57Cr 159.04Cr 144.44Cr 273.36Cr 18TCr 280.99Cr 1.9TCr 758.73Cr 9.67TCr 722.18Cr 706.87Cr 31TCr
Net income -8.45Cr -7.57Cr -6.98Cr -6.34Cr -12Cr -791.9Cr -12Cr -84Cr -33Cr -424.27Cr -32Cr -31Cr -1.34TCr 7.94Cr 7.12Cr 6.56Cr 5.96Cr 11Cr 744.06Cr 12Cr 79Cr 31Cr 398.64Cr 30Cr 29Cr 1.26TCr
Net Debt 105.84Cr 95Cr 87Cr 79Cr 150.35Cr 9.92TCr 154.54Cr 1.05TCr 417.3Cr 5.32TCr 397.2Cr 388.77Cr 17TCr 84Cr 75Cr 69Cr 63Cr 119.38Cr 7.88TCr 122.71Cr 831.63Cr 331.34Cr 4.22TCr 315.38Cr 308.7Cr 13TCr
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
10/26/10 $46.47 +0.65% 10,35,990
09/26/09 $46.17 +0.59% 17,09,146
06/26/06 $45.90 +3.05% 16,73,442
05/26/05 $44.54 -2.94% 19,43,983
04/26/04 $45.89 +0.44% 21,79,091
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
46.47USD
Average target price
57.74USD
Spread / Average Target
+24.25%
  1. Stock Market
  2. Stocks
  3. ALKS Stock